Skip to main content
. Author manuscript; available in PMC: 2024 Nov 4.
Published in final edited form as: Cancer Lett. 2024 Jun 7;597:217023. doi: 10.1016/j.canlet.2024.217023

Fig. 3. Co-inhibition of TrkA and JAK2 enhances apoptosis of breast cancer cells.

Fig. 3.

Annexin V flow cytometry of SKBRM (A) or BT474-TtzmR (B) cells after treatment with vehicle, Entrectinib, Pacritinib, or combination. Cells were counterstained with propidium iodide (PI). Representative flow cytometry plots are displayed for each treatment condition. Western blot analysis of SKBRM (C) or BT474-TtzmR (D) for cleaved and total PARP after single agent or combination therapy treatment. Densitometry values (normalized to β-actin) are displayed below each blot. Caspase 3/7 activity of SKBRM (E) and BT474-TtzmR (F) after single agent or combination therapy treatment. Data of at least three experimental repeats are presented as mean ± SEM. One-way ANOVA with Tukey’s multiple comparison post hoc test was used to compare p values.